Skip to main content

Benevich Eric's Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Apr 17, 2024

Accession no.
0000914475-24-000111
Filed
Apr 17, 2024
Trade date
Apr 15, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.64M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Benevich EricCIK 0001643653Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 15, 2024Common StockMOption exerciseAcquired+7,231$81.49+$589,254.1948,009Direct
Apr 15, 2024Common StockSSaleDisposed−7,231$133.36−$964,326.1640,778Direct
Apr 15, 2024Common StockMOption exerciseAcquired+12,587$81.05+$1,020,176.3553,365Direct
Apr 15, 2024Common StockSSaleDisposed−12,587$133.36−$1,678,602.3240,778Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 15, 2024Common StockMOption exerciseDisposed−7,231$81.49−$589,254.1926,292Direct
Apr 15, 2024Common StockMOption exerciseDisposed−12,587$81.05−$1,020,176.350Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)